ResearcherUniversity of OxfordActive in the last 2 years
Frances W. Willenbrock
Matched on ORCID iD 0000-0001-6038-944X; OpenAlex author ID A5048378829. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 5
- Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control. Co-author DOI 10.1136/gutjnl-2024-333492↗
- Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy. Co-author DOI 10.1126/sciadv.adm9071↗
- Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognostic Biomarker. First author DOI 10.3390/curroncol29040206↗
- Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1038/s41416-020-01120-z↗
- TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. Co-author DOI 10.1053/j.gastro.2021.04.044↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Eric E. O’Neill · 4 shared papers, 2021–2025 · strength 0.65
- Paper Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour contro… DOI 10.1136/gutjnl-2024-333492↗
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Daniel Llwyd Hughes · 4 shared papers, 2021–2024 · strength 0.63
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognos… DOI 10.3390/curroncol29040206↗
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Somnath Mukherjee · 4 shared papers, 2021–2024 · strength 0.63
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper Predicting Early Disease Recurrence of Pancreatic Cancer following Surgery: Determining the Role of NUDT15 as a Prognos… DOI 10.3390/curroncol29040206↗
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Simei Go · 2 shared papers, 2024–2025 · strength 0.44
- Paper Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour contro… DOI 10.1136/gutjnl-2024-333492↗
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Michael Eyres · 2 shared papers, 2021–2024 · strength 0.31
- Paper Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized thera… DOI 10.1126/sciadv.adm9071↗
- Paper TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. DOI 10.1053/j.gastro.2021.04.044↗
- Shannon Nicole Russell · 1 shared paper, 2025 · strength 0.22
- Mathias Tesson · 1 shared paper, 2025 · strength 0.22
- Keaton Ian Jones · 1 shared paper, 2025 · strength 0.22
- Jennifer P. Morton · 1 shared paper, 2025 · strength 0.22
- Alex Nicolas Gordon-Weeks · 1 shared paper, 2025 · strength 0.22
- Tim Maughan · 2 shared papers, 2021 · strength 0.21
- Paper Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradio… DOI 10.1038/s41416-020-01120-z↗
- Paper TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes. DOI 10.1053/j.gastro.2021.04.044↗
- Eric O’Neill · 1 shared paper, 2022 · strength 0.20
- Christopher Mark Jones · 1 shared paper, 2021 · strength 0.12
- Chris N Hurt · 1 shared paper, 2021 · strength 0.12
- Zenobia D’Costa · 1 shared paper, 2021 · strength 0.10
- Simone Lanfredini · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.